Comparing urine tests to cystoscopy for monitoring bladder cancer
A Randomized Cross-Over Study to Evaluate Patient Preference and Satisfaction With Urine-based Molecular Testing Versus Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
This study is trying to see if people with nonmuscle invasive bladder cancer prefer a simple urine test over the more invasive cystoscopy for monitoring their condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 107 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Scottsdale, Arizona) |
| Trial ID | NCT06126796 on ClinicalTrials.gov |
What this trial studies
This study evaluates patient preferences between urine-based molecular testing (CxBladder Monitor) and traditional cystoscopy for surveillance of nonmuscle invasive bladder cancer (NMIBC). The urine test is a noninvasive method that analyzes biomarkers related to cancer recurrence, while cystoscopy involves a more invasive examination of the bladder. Participants will provide urine samples and complete online surveys to share their experiences and preferences regarding these two monitoring methods.
Who should consider this trial
Good fit: Ideal candidates are individuals with a history of nonmuscle invasive bladder cancer who have been disease-free for at least six months and can provide urine samples.
Not a fit: Patients with non-urothelial bladder cancer or those with significant variant histology may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a less invasive and more patient-friendly approach for monitoring bladder cancer recurrence.
How similar studies have performed: Other studies have explored urine-based tests for cancer monitoring, showing promising results, but this specific comparison with cystoscopy is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female with a history of histologically confirmed nonmuscle invasive bladder cancer (NMIBC) who have at least 6 months of disease-free survival from last recurrence. * Able to provide urine for testing and comply with study protocol. * Have an email address and be willing to complete surveys online. Exclusion Criteria: * History of non-urothelial bladder cancer (primary squamous, adenocarcinoma, and small cell carcinoma) * Patients with predominant (\>50%) variant histology * Patients with a history of upper tract and/or urethral cancer * Women who are pregnant
Where this trial is running
Scottsdale, Arizona
- Mayo Clinic in Arizona — Scottsdale, Arizona, United States (Recruiting)
Study contacts
- Principal investigator: Mark D. Tyson, M.D., M.P.H. — Mayo Clinic
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.